Proton pump inhibitors and bone fractures?

American Journal of Gastroenterology

Volumn 104, Issue SUPPL. 2, 2009, Pages

  Laine, Loren ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; BENZIMIDAZOLE; CALCIUM; CIMETIDINE; CORTICOSTEROID; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; WARFARIN;

ARTICLE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CLINICAL TRIAL; DENMARK; DISEASE ASSOCIATION; DOSE RESPONSE; FRACTURE; HIP FRACTURE; HUMAN; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SPINE FRACTURE; STOMACH ACID; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; WRIST FRACTURE;

ANTI-ULCER AGENTS; CAUSALITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FRACTURES, BONE; HIP FRACTURES; HUMANS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 61949298845     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.48     Document Type: Article

References (16)

1. Vestergaard P, Rejnmark L, Mosekilde L. Has mortality after a hip fracture increased? J Am Geriatr Soc 2007;55:17206.
2. Yang YX, Lewis JD, Epstein S. et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:294753.
3. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:7683.
4. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:31926.
5. Mamdani M, Upshur RE, Anderson G et al. Warfarin therapy and risk of hip fracture among elderly patients. Pharmacotherapy 2003;23:14.
6. Grisso JA, Kelsey JL, OBrien LA et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 1997;145:78693.
7. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Safety 2002;25:46771.
8. Legator MS, Morris DL. What did Sir Bradford Hill really say? Arch Environ Health 2003;58:71820.
9. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:93945.
10. OConnell MB, Madden DM, Murray AM et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:77881.
11. Graziani G, Como G, Badalamenti S et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dialysis Transplant 1995;10:137680.
12. Serfaty-Lacrosniere C, Wood RJ, Voytko D et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Col Nutr 1995;14:3648.
13. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calc Tissue Int 1986;38:1235.
14. Mizunashi K, Furukawa Y, Katano K et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calc Tissue Int 1993;53:215.
15. Persson P, Gagnemo-Persson R, Chen D et al. Gastrectomy causes bone loss in the rat: is lack of gastric acid responsible? Scand J Gastroenterol 1993;28:3016.
16. Kannus P, Niemi S, Parkkari J et al. Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet 1999;353:8025.